Back to results
US 2021/0275501 A1Published application
Ocular formulations for drug-delivery and protection of the anterior segment of the eye
AssigneePanOptica, Inc.
InventorsDavid P. BINGAMAN, Paul G. CHANEY, Martin B. WAX
Life of this patent
Estimating the term…
Abstract
The present application relates to topical formulations comprising Compound-I or its free base, and a second active agent selected from nicotinic acid, nicotinamide, and vitamin K, and a combination thereof, for treating ocular neovascularization. The present application also relates to pharmaceutical compositions comprising particles of Compound-I or its free base, and suspension formulations comprising the particle compositions of Compound-I or its free base.
Claims20
A topical, ocular, suspension formulation, comprising:
- a. particles of a first active agent of Formula II:
- or a pharmaceutically acceptable salt thereof;
- and
- b. one or more pharmaceutically acceptable excipients selected from hydroxy propyl methyl cellulose (HPMC), carboxylmethyl cellulose and salts thereof, and hydroxyl ethyl cellulose (HEC);
- wherein the first active agent or the pharmaceutically acceptable salt thereof is present in about 0.1% to about 2.0% (w/v), and the particles have a mean diameter of between 100 nm and 100 μm.
2 more elements
Dependencies are inferred from the claim text.